San Donato Hospital
Prostate cancer treatment cost in Italy is determined by the diagnostic baseline and chosen therapeutic modality. A PSA test typically costs $100 to $100, while a robotic da Vinci prostatectomy runs from $25,200 to $28,000. Total expenses depend on the cancer stage, hospital tier, and surgical approach. International patients can save 30-50% compared to US private healthcare. Top treatment centers are located in Milan, Rome, and Bologna.
Typical Prostate Cancer Treatment Costs in Italy
Bookimed Expert Insight: For high-precision requirements, robotic surgery at Ospedale San Carlo di Nancy is a top-rated choice. Patients seeking world-renowned experts should consider San Raffaele, where Professor Francesco Montorsi performs urological surgeries. If multidisciplinary care is needed, JCI-accredited Maria Cecilia Hospital provides specialized urological oncology. Early-stage patients benefit from standard laparoscopic options at San Donato Hospital to manage costs effectively.
| Italy | Turkey | Austria | |
| Transurethral resection of the prostate (TURP) | from $3,600 | from $3,580 | from $5,500 |
| Tomotherapy | from $32,000 | from $12,000 | from $30,000 |
| Robotic da Vinci prostatectomy | from $25,206 | from $17,000 | from $20,000 |
| Radiotherapy for prostate cancer | from $18,000 | from $4,000 | from $14,000 |
| Proton-beam therapy | from $70,000 | from $70,000 | from $80,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Prostate cancer treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Prostate cancer treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Prostate cancer treatment journey.
Prof. Montorsi has performed over 8,000 urology surgeries, specializing in minimally invasive and robotic techniques for prostate cancer at San Raffaele.
Head of Radiotherapy at San Raffaele Hospital – Prof. Di Muzio specializes in high-precision hypofraction methods for prostate cancer, with over 33 years of experience of experience.
Dr. Alessandro Calarco is a skilled urologist with expertise in minimally invasive and endourological procedures. He performs percutaneous lithotripsy, ureterorenoscopy, tumor ablation, and advanced reconstructive surgeries. Dr. Calarco has received international recognition for his clinical work and research. He completed advanced training in Sweden and the UK.
Dr. Calarco graduated with top honors from Università Cattolica del Sacro Cuore in Rome. He completed his Urology specialization and earned a PhD in Oncological Urology at the same university. His research focuses on prostate cancer biomarkers and exosomes. He has also helped develop clinical protocols for hormone-refractory prostate cancer.
He serves as National Head of Urology for SPIGC and is a member of the European Board of Urology. Dr. Calarco holds an international patent for a device that improves percutaneous nephrolithotripsy. He has published extensively and received several awards for surgical innovation and education.
The doctor is the Director of the Radiation Oncology Unit and holds a degree in Medicine and Surgery from Università La Sapienza, Rome, Italy, with a specialization in Radiation Oncology from Università Cattolica del Sacro Cuore, Rome, Italy.
Specializing in high-tech applications in Radiation Oncology, the doctor is proficient in Intensity Modulated Radiation Therapy, Stereotactic Radiation Therapy, Adaptive Radiation Therapy, and Brachytherapy. The doctor focuses on optimizing radiation treatments using advanced imaging for target volume delineation and integrating radiotherapy with surgery and chemotherapy, particularly for Upper Gastro-intestinal, Prostate, and Lung cancers.
The doctor serves as an Assistant Professor in Radiation Oncology at Università Cattolica del Sacro Cuore and is a faculty member at the ESTRO Teaching Course.
Written by Anna Leonova
Written by Olena Sikoza
Italy offers elite prostate cancer care at IRCCS-accredited facilities like San Raffaele in Milan and Ospedale San Carlo di Nancy in Rome. These centers feature the da Vinci robotic system for nerve-sparing surgery. Leading specialists like Prof. Francesco Montorsi have performed over 8,000 specialized urological procedures.
Bookimed Expert Insight: While many search for general hospital rankings, our data suggests focusing on surgeon-specific caseloads within Milan's IRCCS-accredited cluster. San Raffaele stands out not just for volume, but for clinical research integration. Their specialists often serve as national coordinators for advanced protocols like brachytherapy, ensuring patients access treatment standards that regional centers may not yet offer.
Patient Consensus: Patients emphasize that accessing high-volume surgeons who perform over 200 annual prostatectomies is more critical than the hospital's general reputation. Many recommend bringing original pathology slides for a second opinion at major Milanese centers to ensure accurate staging before surgery.
Italy offers advanced medical technologies focusing on robotic surgery and precision oncology. Systems like Da Vinci enable minimally invasive prostatectomies with high success rates. Specialized centers also provide proton therapy and high-precision hypofraction methods. These institutions maintain international accreditations for complex oncology and urology care.
Bookimed Expert Insight: Data shows Italy's leading research hospitals achieve massive surgical volumes. San Raffaele in Milan performs over 52,000 operations annually. This high frequency allows surgeons like Dr. Francesco Montorsi to complete over 8,000 procedures. Patients benefit from this extreme specialization. It often leads to better preservation of urinary and sexual function compared to lower-volume centers.
Patient Consensus: Patients note that Italian centers offer high robotic expertise with faster scheduling than other European destinations. They emphasize confirming the surgeon performs over 300 robotic cases annually to ensure the best functional outcomes.
Average waiting times for prostate cancer treatment in Italy range from 30 to 93 days depending on clinical urgency. The Italian National Healthcare System (SSN) prioritizes urgent cases within 72 hours. Non-urgent oncological surgeries typically proceed within approximately 29 to 35 days.
Bookimed Expert Insight: High-volume research centers like San Raffaele in Milan manage over 52,000 operations annually. Patients can significantly reduce wait times by accessing these accredited facilities through private or Libera professione channels. This approach bypasses standard public queues while maintaining access to top researchers like Prof. Dr. Francesco Montorsi.
Patient Consensus: Patients note that requesting a specific urgency code from their urologist is vital for faster scheduling. Many suggest using online regional tracking systems to monitor and appeal potential treatment delays.
Patients should prioritize questions about specific Gleason scores and the surgeon's personal robotic prostatectomy volume. Inquire about multidisciplinary tumor boards at facilities like San Raffaele. Clarify if treatments like da Vinci robotic surgery or proton-beam therapy fit your specific cancer stage and grade.
Bookimed Expert Insight: Italian centers of excellence like San Raffaele and San Carlo di Nancy often combine clinical care with intensive research. High-volume specialists like Dr. Francesco Montorsi have performed over 8,000 surgeries. This level of expertise often leads to better preservation of nerve function and faster recovery. Always ask if your case will be reviewed by a multidisciplinary equipe including radiation oncologists.
Patient Consensus: Patients note it is essential to bring a printed PSA history and biopsy report. They emphasize asking for a written staging summary to avoid confusion during follow-up care.